SERMs and SERMs with estrogen for postmenopausal osteoporosis.
Bone loss with aging places postmenopausal women at a higher risk for osteoporosis and its consequences such as fractures, pain, disability, and increased morbidity and mortality. Approximately 200 million patients worldwide are affected. The Third National Health and Nutrition Examination Survey (NHANES III) estimated that up to 18% of US women aged 50 and older have osteoporosis and up to 50% have osteopenia. Greater than 2 million osteoporotic related fractures occurred in the United States with direct healthcare costs exceeding $17 billion. Hormone Replacement Therapy (HRT) was a popular option for postmenopausal women before the Women's Health Initiative (WHI). Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene. There are concerns about long term safety and compliance. Therefore, other agents are under investigation. SERMs are a diverse group of agents that bind to the estrogen receptor and each SERM appears to have a unique set of clinical responses, which are not always consistent with the typical responses seen with other SERMs. This article will discuss the SERMs approved in the United States, tamoxifene and raloxifene, and investigational SERMs. The ideal SERM would include the beneficial effects of estrogen in bone, heart and the central nervous system, with neutral or antagonistic effects in tissues where estrogen effects are undesirable(breast and endometrium). A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC). This novel approach is currently being evaluated with bazodoxifene which could yield the beneficial effects of estrogens and SERMS, while potentially being more tolerable and safer than either therapy alone.
Bolognese
Michael A
MA
Bethesda Health Research, Bethesda, MD, USA. mbolognese@erols.com
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators
Obstet Gynecol. 2005 Jun;105(6):1397-404
15932835
J Clin Pharmacol. 2006 Jan;46(1):52-8
16397284
Endocrinology. 2008 Dec;149(12):6084-91
18703623
J Bone Miner Res. 2008 Apr;23(4):525-35
18072873
Breast Cancer Res Treat. 2002 May;73(2):161-75
12088118
Clin Biomech (Bristol, Avon). 2002 Feb;17(2):81-8
11832257
Menopause. 2003 Jul-Aug;10(4):337-44
12851517
Breast Cancer Res Treat. 2001 Jan;65(2):125-34
11261828
Curr Med Res Opin. 2005 Sep;21(9):1441-52
16197663
J Bone Miner Res. 2007 Mar;22(3):465-75
17144789
JAMA. 1999 Jun 16;281(23):2189-97
10376571
Fertil Steril. 2009 Sep;92(3):1045-1052
19635616
Am J Cardiol. 2006 Feb 15;97(4):520-7
16461049
Obstet Gynecol. 2001 Jul;98(1):91-6
11430963
Arch Intern Med. 2000 Dec 11-25;160(22):3444-50
11112238
JAMA. 1999 Aug 18;282(7):637-45
10517716
JAMA. 2006 Jun 21;295(23):2727-41
16754727
J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61
15572757
N Engl J Med. 2010 Feb 25;362(8):686-96
20181970
N Engl J Med. 2006 Jul 13;355(2):125-37
16837676
Obstet Gynecol. 2004 Oct;104(4):837-44
15458908
Curr Top Med Chem. 2006;6(3):181-202
16515478
Menopause. 2005 Jul-Aug;12(4):444-52
16037760
Menopause. 2006 May-Jun;13(3):377-86
16735934
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
9747868
Arch Intern Med. 2004 May 24;164(10):1108-12
15159268
Fertil Steril. 2009 Sep;92(3):1039-1044
19635614
Arch Intern Med. 1991 Sep;151(9):1842-7
1888251
J Bone Miner Res. 2005 Sep;20(9):1514-24
16059623
Obstet Gynecol. 1999 Apr;93(4):558-65
10214833
Bone. 2009 May;44(5):734-43
19195497
Reprod Sci. 2008 Dec;15(10):984-92
19088368
N Engl J Med. 1997 Dec 4;337(23):1641-7
9385122
Am J Obstet Gynecol. 1997 Dec;177(6):1458-64
9423751
J Ultrasound Med. 1999 Jul;18(7):503-12
10400054
Obstet Gynecol Surv. 2008 Mar;63(3):163-81
18279543
Fertil Steril. 2009 Sep;92(3):1025-1038
19635615
J Bone Miner Res. 1997 Nov;12(11):1761-8
9383679
Acta Obstet Gynecol Scand. 2006;85(2):135-42
16532904
Lancet. 2000 Mar 4;355(9206):848-9
10711957
Climacteric. 2005 Sep;8(3):214-20
16390753
Am J Psychiatry. 2005 Apr;162(4):683-90
15800139
Menopause. 1999 Fall;6(3):188-95
10486787
Arch Intern Med. 2004 Apr 26;164(8):871-9
15111373
Gynecol Oncol. 2002 May;85(2):388-90
11972407
Fertil Steril. 2009 Sep;92(3):1018-1024
19635613
Menopause. 2005 Mar;12(2):160-4
15772563
Drugs. 2006;66(2):191-221
16451093
J Bone Miner Res. 1996 Jun;11(6):835-42
8725181
Maturitas. 2005 Oct 16;52(2):87-101
15967604
Obstet Gynecol. 2004 Feb;103(2):261-6
14754693
Endocrinology. 2005 Sep;146(9):3999-4008
15961563
N Engl J Med. 2001 Apr 19;344(16):1207-13
11309635